Botox Cosmetic relaxes a muscle. Juvederm adds volume. They fix different problems, and no trial has ever tested one against the other. If a line only shows when you move your face, that is a muscle problem and a toxin is the tool. If something looks hollow, deflated or creased at rest, that is a volume problem and a filler is the tool.
Botox Cosmetic is onabotulinumtoxinA, a botulinum toxin type A. It blocks the release of acetylcholine at the nerve ending, so the muscle it is injected into stops contracting fully. It occupies no space. It cannot plump a lip or lift a cheek.
Juvederm is not one product — it is a family of hyaluronic acid gels, and each one has its own FDA approval, its own area and its own trial. Juvederm Ultra XC, Ultra Plus XC, Voluma XC, Vollure XC, Volbella XC, Volux XC and Skinvive are approved for different parts of the face, and a number from one of them does not transfer to another.
There is no head-to-head trial of any filler against any botulinum toxin, for any indication. There cannot be a meaningful one, because they are not treating the same thing. What does exist is a small randomised literature on using both together — and that is the reason so many people are told they need both.
Approved through the FDA's premarket approval route as a Class III device, which required trial evidence for a named area of the face.
Approved as a drug, with a label that names the muscle group for each area.
Nothing about a muscle changes. The change is there the moment it is injected, though swelling makes the first days unreliable.
No volume is added. Depth that is already etched into the skin at rest is not what it targets.
Ultra XC — facial wrinkles and folds such as nasolabial folds, and the lips and perioral area in adults over 21. Ultra Plus XC — facial wrinkles and folds, and it carries no US lip indication. Vollure XC — facial wrinkles and folds. Voluma XC — cheeks (2013), chin (2020) and temples (2023). Volbella XC — lips and perioral lines (2016) and the infraorbital hollow (2021). Volux XC — jawline definition (2022). Skinvive — skin smoothness of the cheeks (2023) and neck lines (2026).
Glabellar lines (12 April 2002), lateral canthal lines, which are crow's feet (11 September 2013), forehead lines (2 October 2017) and platysma bands (18 October 2024).
Juvederm syringes are supplied at 1.0 mL, with 0.55 mL fills approved for several products.
The label gives 20 Units for glabellar lines, 24 Units for lateral canthal lines, 40 Units total when forehead and glabellar lines are treated together, and 26, 31 or 36 Units for platysma bands.
Voluma XC in the cheeks: 85.6% of treated people still met a one-grade improvement at 6 months and 67.1% at 24 months, where the study ended. Ultra XC in the lips: 79.1% at 3 months and 56.4% at 12 months. Vollure XC in nasolabial folds: 93.2% at 6 months, 57.5% at 12 and 59.4% at 18. Volbella XC in the lips: 80.3% at 3 months and 61.8% at 12. Volux XC at the jawline: 69.9% at 6 months and 61.3% at 12. Skinvive in the cheeks: 55.6% at 6 months.
Published trials measured the result at day 30 and day 60; one three-way comparison of three brands followed people for 180 days.
It works within minutes to hours, though a treated area usually takes a day or two to settle and repeat dosing is normal. Juvederm products are among the more enzyme-resistant in laboratory testing, needing higher doses than some other brands.
Nothing dangerous — it just does not work: Filler placed under a line that is purely caused by movement leaves the movement intact, so the line keeps folding. Toxin injected where volume is missing relaxes a muscle that was not the problem, and the hollow stays exactly as it was.
There is one area where the two genuinely overlap. A deep frown line between the brows that is still visible when the face is completely still has a static component that toxin alone under-treats. That is precisely the premise of the studies below.
Some areas belong clearly to one side. Botox Cosmetic has held the lateral canthal line indication since 2013. Crow's feet are lateral canthal lines. No Juvederm or Restylane product carries an indication for that area, and filler used there is off-label - which is legal and routine, but it means no pivotal trial was run there. Lost cheek volume is the mirror image: Voluma XC is approved for it and no toxin is.
Three randomised studies have tested toxin alone against toxin plus a hyaluronic acid filler. None of them compared a filler against a toxin as alternatives — they tested adding one to the other.
A three-arm randomised trial in the lower face, n=90, compared onabotulinumtoxinA alone, a 24 mg/mL cohesive hyaluronic acid gel alone, and both. The combination did better than either alone for all endpoints at most timepoints. The products were Allergan's, so treat it as industry-associated.
A split-face randomised trial of the forehead and glabella, n=20, found comparable results either way at 2, 6 and 12 weeks — everyone improved — and at week 24 the combination side held its effect longer. The authors' own wording was that the combination "may provide a slightly better cumulative benefit".
A glabellar study, n=40, graded Level of Evidence III, gave everyone 18 units of a botulinum toxin the abstract does not name, and added 0.45 mL of hyaluronic acid filler in one arm. The combination arm scored better on the Facial Wrinkle Scale at weeks 20 and 28.
Fair summary: adding filler to toxin in the glabella and forehead appears to stretch and slightly deepen the result at around five to six months: There is no evidence that filler substitutes for toxin on a movement line, or that toxin substitutes for filler where volume is gone.
No trial has compared Juvederm against Botox Cosmetic, and none is planned, because a fair comparison would need both to be treating the same problem: Numbers from a Juvederm trial and numbers from a Botox Cosmetic trial were produced on different scales, by different raters, in different populations. Lining them up beside each other to declare a winner is not a comparison.
The same caution applies to the trials within each family. Most modern filler head-to-heads are non-inferiority designs, which set out only to rule out a difference bigger than a pre-set margin. A non-inferiority result is not a win.
No professional society currently publishes a per-syringe price for either: The American Society of Plastic Surgeons stopped reporting fees for minimally invasive procedures after 2023. Its last figure for hyaluronic acid fillers was $715 for 2023 — and that is a surgeon or physician fee only, excluding facility and anaesthesia costs, averaged across more than ten different products and every area of the face, counted per procedure rather than per syringe. Someone who had three syringes in one visit counts once in that dataset. There is no comparable published current figure for Botox Cosmetic.
Crowdsourced patient-reported figures exist but are self-selected and undated in places. RealSelf's Juvederm page gives an average of $944, drawn from 88 patient reviews and last updated 7 June 2023.
These signs can mean filler has entered a blood vessel. That is a rare event, and it is a medical emergency where time matters in hours.
Any change in vision — blurring, a dark patch, double vision or loss of sight in one eye, during or straight after an injection
Pain that is far worse than the procedure should cause, or pain that keeps building
Skin that turns white or pale in a patch soon after an injection, then goes dusky, blotchy or net-like
Weakness, drooping, slurred speech or confusion
Published guidance treats suspected blockage of the artery to the eye as a same-hour emergency and suspected skin blockage as a same-day emergency. In a review of 511 published blindness cases from 1906 to 2023, 68.2% of the 318 people with a recorded outcome had no recovery of vision, and no treatment used was significantly associated with improvement. Do not wait to see if it settles, and do not assume pain will warn you — in a survey of 52 experienced injectors, pain was mild or absent in 47% of the blocked-vessel events they described.
Swelling is still growing three or more days after treatment instead of settling
A lump appears and will not settle, or one appears weeks or months later
Redness spreads outward from the injection site, or the area becomes hot and tender
Tenderness, firmness or swelling turns up weeks after treatment, sometimes after an illness, a vaccination or dental work — this is a recognised delayed reaction
The product looks like it has moved out of the area that was treated